Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: January 7, 2005
Last updated: February 1, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)